Value20202021202220232024TTMSelling/general/admin expenses8.65 M8.67 M13.07 M21.14 M13.71 M10.06 MResearch & development5.72 M7.67 M6.99 M10.94 M6.2 M4.53 MOperating income15.15 M18.84 M19.92 M31.92 M19.77 M14.57 MNon-Operating Income, Total—201 K2.31 M1.27 M5.29 M4.57 MInterest expense, net of interest capitalized672 K67 K0—585 K553 KNon-Operating Income, excl. Interest Expenses—134 K1.68 M200 K-492 K-873 KUnusual income/expense——629 K1.07 M5.19 M4.89 MPretax income15.19 M21.69 M22.23 M-21.13 M-13.76 M-16.67 MEquity in earnings——————Taxes—0000—Non-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations14.4 M19.13 M19.45 M28.96 M17.32 M15.75 MDiscontinued operations——————Net income14.4 M19.13 M19.45 M28.96 M17.32 M15.75 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders14.4 M19.13 M19.45 M28.96 M17.32 M15.75 MBasic earnings per share (Basic EPS)——-40-60-31-17.11Diluted earnings per share (Diluted EPS)——40.47-60-31-17.11Average basic shares outstanding——480.47 K485.85 K560.17 K4.12 MDiluted shares outstanding——480.47 K485.85 K560.17 K4.12 MEBITDA-9.63 M-7.53 M-12.14 M-31.86 M-19.64 M-11.87 MEBIT-10.48 M-8.36 M-12.4 M-32.1 M-19.98 M-12.78 MCost of revenue1.9 M850 K042 K31 K95 KOther cost of goods sold1.9 M850 K042 K31 K95 KDepreciation & amortization (cash flow)845 K822 K256 K238 K339 K909 K
AIM ImmunoTech Inc
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome.